We will continue to keep our stakeholders informed about our progress and any new developments. Thank you for your continued support.
04/16/2025: FDA approved Elite Valganciclovir Tablets USP 450 mg
01/2025: Elite has successfully collaborated with USP to update two monographs in USP database.
12/2024: IND’s; FDA has agreed with two of Elite 505 (b)(2) approach for Extended-Release in diabetes treatment.
08/2024: NDA; FDA granted Elite You May Proceed for phase 1 clinical study for 505 (b)(2) Extended-Release diabetes treatment.